Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Kirkpatrick

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Materials (Basel, Switzerland)|August 18, 2017
Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?D Lynn Kirkpatrick, Michelle Weiss, Anton Naumov, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2006
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingRyan Williams, Amanda F Baker, Nathan T Ihle, et al.
Molecular Cancer Therapeutics|March 27, 2003
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formationSarah J Welsh, Ryan R Williams, Anne Birmingham, et al.
Journal of Opioid Management|March 28, 2017
In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodoneD Lynn Kirkpatrick, William K Schmidt, Ricardo Morales, et al.
Clinical and Translational Science|March 21, 2024
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteersD Lynn Kirkpatrick, Cari Evans, Linda A Pestano, et al.
Cancers|August 17, 2019
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon NanotubesMd Tanvir Hasan, Elizabeth Campbell, Olga Sizova, et al.
Molecular Cancer Therapeutics|January 19, 2008
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alphaMei Y Koh, Taly Spivak-Kroizman, Sara Venturini, et al.
Neoplasia (New York, N.Y.)|June 22, 2005
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478Bénédicte F Jordan, Matthew Runquist, Natarajan Raghunand, et al.
Molecular Cancer Therapeutics|January 14, 2009
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activityNathan T Ihle, Robert Lemos, David Schwartz, et al.
Journal of Opioid Management|March 3, 2026
Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protectionD Lynn Kirkpatrick, Linda A Pestano, Cari Evans, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Materials (Basel, Switzerland)|August 18, 2017
Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?D Lynn Kirkpatrick, Michelle Weiss, Anton Naumov, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2006
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingRyan Williams, Amanda F Baker, Nathan T Ihle, et al.
Molecular Cancer Therapeutics|March 27, 2003
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formationSarah J Welsh, Ryan R Williams, Anne Birmingham, et al.
Journal of Opioid Management|March 28, 2017
In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodoneD Lynn Kirkpatrick, William K Schmidt, Ricardo Morales, et al.
Clinical and Translational Science|March 21, 2024
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteersD Lynn Kirkpatrick, Cari Evans, Linda A Pestano, et al.
Cancers|August 17, 2019
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon NanotubesMd Tanvir Hasan, Elizabeth Campbell, Olga Sizova, et al.
Molecular Cancer Therapeutics|January 19, 2008
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alphaMei Y Koh, Taly Spivak-Kroizman, Sara Venturini, et al.
Neoplasia (New York, N.Y.)|June 22, 2005
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478Bénédicte F Jordan, Matthew Runquist, Natarajan Raghunand, et al.
Molecular Cancer Therapeutics|January 14, 2009
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activityNathan T Ihle, Robert Lemos, David Schwartz, et al.
Journal of Opioid Management|March 3, 2026
Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protectionD Lynn Kirkpatrick, Linda A Pestano, Cari Evans, et al.
Pageof 4